Osaka University

Sysmex Corporation

Takahiro Tougan

Ken Ishii

Toshihiro Horii

Yuji Toya

Hiroshi Nojima

Daisuke Okuzaki

Disclosed is a blood analyzer including: a first sample preparation unit configured to prepare, from a blood sample, a first measurement sample for measuring a red blood cell infected with malaria; a second sample preparation unit configured to prepare, from the blood sample, a second measurement sample for measuring intrinsic fluorescence of a red blood cell; a light source unit configured to apply light to the first and the second measurement samples; a detection unit configured to detect fluorescence and scattered light generated from the first measurement sample to which light has been applied, and detect intrinsic fluorescence generated from the second measurement sample to which light has been applied; and an information processing unit configured to generate information about malaria infection based on fluorescence and scattered light detected from the first measurement sample, and generate information about iron-deficiency anemia based on intrinsic fluorescence detected from the second measurement sample.

Blood analyzer

The present invention provides a vaccine for preventing and/or treatinginfections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant.X-A-B-X-Y-X-(Y)n-X-(Y)n-X&#x2003;&#x2003;(1)(In the formula, Xrepresents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; Xrepresents the 73th to 177th amino acid residues; Xrepresents the 178th to 258th amino acid residues; Xrepresents the 259th to 289th amino acid residues; Xrepresents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1).

Malaria vaccine

The present invention provides a vaccine for preventing and/or treatinginfections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant.X-A-B-X-Y-X-(Y)n-X-(Y)n-X&#x2003;&#x2003;(1)(In the formula, Xrepresents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; Xrepresents the 73th to 177th amino acid residues; Xrepresents the 178th to 258th amino acid residues; Xrepresents the 259th to 289th amino acid residues; Xrepresents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.)

A method for amplifying a trace amount of mRNA includes adding a dummy RNA to a solution containing the trace amount of mRNA, so as to prepare a mixed solution; synthesizing an anti-sense DNA by reverse transcription, which uses the mixed solution as a template; synthesizing a sense DNA which is complementary to the anti-sense DNA thus synthesized, so as to generate a double-strand DNA made of the sense DNA and the anti-sense DNA; ligating an RNA polymerase promoter sequence to the double-strand DNA thus generated, on a sense DNA 5' end side of the double-strand DNA, so as to prepare a double-strand DNA for amplification; and amplifying, by using RNA polymerase, an RNA from the double-strand DNA for amplification.

Growing community of inventors

Suita, Japan

Takahiro Tougan